Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.
Surveillance E, and End Results (SEER) Program. Cancer Stat Facts: Colorectal Cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 9/10/2022.
Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70(3):145–164. https://doi.org/10.3322/caac.21601.
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.
Vincent G, Velkoff V. The next four decades: the older population in the United States - 2010 to 2050: Population estimates and projections. . U.S. Census Bureau, May 2010.
U.S. Census Bureau. 2012-2016 American Community Survey 5-Year Estimates. https://www.census.gov/programs-surveys/acs/technical-documentation/table-and-geography-changes/2016/5-year.html. Accessed 9/9/2022.
Desantis CE, Miller KD, Dale W et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin 2019;69(6):452–467. https://doi.org/10.3322/caac.21577.
SEER Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 9/10/2022.
Walter V, Boakye D, Weberpals J, et al. Decreasing use of chemotherapy in older patients with stage III colon cancer irrespective of comorbidities. J Nat Compr Cancer Netw. 2019;17(9):1089–99. https://doi.org/10.6004/jnccn.2019.7287.
Chang HJ, Lee KW, Kim JH, et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol. 2012;23(4):911–8. https://doi.org/10.1093/annonc/mdr329.
Article CAS PubMed Google Scholar
Antonio M, Carmona-Bayonas A, Saldana J et al. Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study. Clin Colorectal Cancer 2018;17(1):e59-e68. https://doi.org/10.1016/j.clcc.2017.09.003. Well-designed elderly-specific trial with a good review of geriatric assessment.
Lund CM, Vistisen KK, Olsen AP, et al. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO). Br J Cancer. 2021;124(12):1949–58. https://doi.org/10.1038/s41416-021-01367-0.
Article CAS PubMed PubMed Central Google Scholar
Francois E, Pernot M, Ronchin P et al. NACRE: A randomized study comparing short course radiotherapy with radiochemotherapy for locally advanced rectal cancers in the elderly—Preliminary results. J Clin Oncol 2021;39(3_suppl):4–4. https://doi.org/10.1200/JCO.2021.39.3_suppl.4. Elderly-specific rectal cancer trial.
Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59. https://doi.org/10.1016/s0140-6736(11)60399-1.
Article CAS PubMed PubMed Central Google Scholar
Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol. 2016;27(1):121–7. https://doi.org/10.1093/annonc/mdv491.
Article CAS PubMed Google Scholar
Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85. https://doi.org/10.1016/S1470-2045(13)70154-2.
Article CAS PubMed Google Scholar
Hamaguchi T, Takashima A, Mizusawa J et al. A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT). J Clin Oncol 2022;40(4_suppl):10–10. https://doi.org/10.1200/JCO.2022.40.4_suppl.010.
Lonardi S, Schirripa M, Buggin F et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. J Clin Oncol 2020;38(15_suppl):4002–4002. https://doi.org/10.1200/JCO.2020.38.15_suppl.4002.
Petrioli R, Chirra M, Messuti L, et al. Efficacy and safety of regorafenib with 2/1 schedule for patients ≥ 75 years with metastatic colorectal cancer (mCRC) after failure of 2 lines of chemotherapy. Clin Colorec Cancer. 2018;17(4):307–12. https://doi.org/10.1016/j.clcc.2018.02.005.
Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–6. https://doi.org/10.1056/NEJMsa012528.
Paillaud E, Caillet P, Laurent M et al. Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment. Clin Interven Aging. 2014:1645. https://doi.org/10.2147/cia.s57849.
Chaibi P, Magne N, Breton S, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol. 2011;79(3):302–7. https://doi.org/10.1016/j.critrevonc.2010.08.004.
Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44. https://doi.org/10.1038/bjc.2015.120.
Article CAS PubMed PubMed Central Google Scholar
Li D, Sun CL, Kim H et al. Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol 2021;7(11):e214158. https://doi.org/10.1001/jamaoncol.2021.4158. Trial demonstrating the feasibility of geriatric assessment-guided therapy and subsequently improved patient outcomes.
Mohile SG, Mohamed MR, Xu H et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021;398(10314):1894–1904. https://doi.org/10.1016/S0140-6736(21)01789-X. Trial demonstrating the feasibility of geriatric assessment-guided therapy and subsequently improved patient outcomes.
Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44. https://doi.org/10.1038/bjc.2015.120.
Article CAS PubMed PubMed Central Google Scholar
Dotan E, Walter LC, Browner IS et al. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Nat Compr Cancer Netw 2021;19(9):1006–1019. https://doi.org/10.6004/jnccn.2021.0043.
Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–47. https://doi.org/10.1200/jco.2018.78.8687.
Article PubMed PubMed Central Google Scholar
Caillet P, Laurent M, Bastuji-Garin S, et al. Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment. Clin Interv Aging. 2014;9:1645–60. https://doi.org/10.2147/CIA.S57849.
Article PubMed PubMed Central Google Scholar
Basso U, Falci C, Brunello A et al. Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP). J Clin Oncol 2011;29(15_suppl):9065–9065. https://doi.org/10.1200/jco.2011.29.15_suppl.9065.
Caplan GA, Williams AJ, Daly B, Abraham K. A randomized, controlled trial of comprehensive geriatric assessment and multidisciplinary intervention after discharge of elderly from the emergency department–the DEED II study. J Am Geriatr Soc. 2004;52(9):1417–23. https://doi.org/10.1111/j.1532-5415.2004.52401.x.
Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017;9:CD006211. https://doi.org/10.1002/14651858.CD006211.pub3.
Frese T, Deutsch T, Keyser M, Sandholzer H. In-home preventive comprehensive geriatric assessment (CGA) reduces mortality–a randomized controlled trial. Arch Gerontol Geriatr. 2012;55(3):639–44. https://doi.org/10.1016/j.archger.2012.06.012.
Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015;13(9):1120–30. https://doi.org/10.6004/jnccn.2015.0137.
Article PubMed PubMed Central Google Scholar
Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65. https://doi.org/10.1200/JCO.2011.34.7625.
Article CAS PubMed PubMed Central Google Scholar
Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31. https://doi.org/10.1200/JCO.2007.10.6559.
Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005. https://doi.org/10.1002/cncr.21422.
Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290–6. https://doi.org/10.1200/JCO.2010.30.6985.
Article PubMed PubMed Central Google Scholar
Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–9. https://doi.org/10.1046/j.1532-5415.2001.49281.x.
Article CAS PubMed Google Scholar
Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–72. https://doi.org/10.1093/annonc/mdr587.
Article CAS PubMed Google Scholar
Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366–71. https://doi.org/10.1200/jco.2015.65.4327.
Article PubMed PubMed Central Google Scholar
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86. https://doi.org/10.1002/cncr.26646.
Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–37. https://doi.org/10.1634/theoncologist.5-3-224.
Article CAS PubMed Google Scholar
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345(8955):939–44. https://www.ncbi.nlm.nih.gov/pubmed/7715291. Accessed 9/10/2022.
O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300. https://doi.org/10.1200/JCO.1998.16.1.295.
Article CAS PubMed Google Scholar
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17(5):1356–63. https://www.ncbi.nlm.nih.gov/pubmed/10334519. Accessed 9/10/2022.
Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Eng J Med. 2001;345(15):1091–7. https://doi.org/10.1056/nejmoa010957.
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med. 2004;350(23):2343–51. https://doi.org/10.1056/nejmoa032709.
André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16. https://doi.org/10.1200/jco.2008.20.6771.
Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant Tre. J Clin Oncol. 2012;30(27):3353–60. https://doi.org/10.1200/jco.2012.42.5645.
留言 (0)